Brief: Theratechnologies Inc Announces New Findings For Lead Investigational Compound Th1902 For Treatment Of Several Additional Cancers
08/12/2020 12:15
Dec 8 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES INC - ANNOUNCES NEW FINDINGS FOR LEAD
INVESTIGATIONAL COMPOUND TH1902 FOR TREATMENT OF SEVERAL
ADDITIONAL CANCERS
* THERATECHNOLOGIES INC - CONFIRMED THAT TH1902 COULD BE
ADMINISTERED AT THREE TIMES MAXIMUM TOLERATED DOSE (MTD) OF
DOCETAXEL ALONE
* THERATECHNOLOGIES INC - TH1902 SHOWS PRE-CLINICAL IN VIVO
EFFICACY IN COLORECTAL, PANCREATIC, MELANOMA AND ENDOMETRIAL
CANCERS
Source text for Eikon: ID:nGNX8L57CL
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process